Compare GE Vernova Inc (GEV) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Vernova Inc vs Repligen Corporation Common Stock — how do they compare? GE Vernova Inc trades at $923.41 (market cap $267.41B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: GE Vernova Inc is far larger — about 24× Repligen Corporation Common Stock's market cap, and GE Vernova Inc pays a 0.2% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold GE Vernova Inc for 37 Days and Repligen Corporation Common Stock for 0 Days on average.
| GEV | RGEN | |
|---|---|---|
Market Cap | $267.41B | $11.14B |
Volume | 1,900,074 | 1,259,263 |
Sector | Industrials | Health |
52-Week High | $1.17K | $194.57 |
52-Week Low | $547.96 | $102.87 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | $257.08B | $11.02B |
Dividend Yield | 0.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Vernova (GEV) trades at $1,004.04, up 0.73% with strong bullish momentum from technical indicators and positive analyst sentiment. The stock shows impressive fundamental performance with 2026 revenue projected at $41.4B and net income of $9.5B, representing a 23.03% profit margin. Recent catalysts include securing the first US construction permit for its BWRX-300 small modular reactor and strong backlog growth to $176B, positioning the company to benefit from AI-driven power demand.
The outlook remains positive with 76% analyst buy ratings and a $1,270 consensus price target suggesting 26% upside potential. Key risks include valuation concerns with P/E of 28.79 and EV/EBITDA of 85.64 appearing elevated, along with execution challenges in the wind power segment. The stock's strong cash flow generation and positioning in the AI power infrastructure theme support continued growth prospects despite rich valuations.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
